Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring (fibrosis) of lung tissue, ...

Most ICBs in England do not have effective referral pathways for diagnosing and managing liver disease, an analysis has shown ...

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

Fortier hopes the discovery that this pathway reverses fibrosis leads to exploration of additional brakes on fibrosis. "So much work on fibrosis has focused on how we can prevent it, but when a ...

They are key to the initiation and resolution of various types of lung injuries, but also are involved in pathways that lead to lung scarring (fibrosis). It is currently unclear what mechanisms ...

Radiation-induced fibrosis (RIF) represents one of the most ... RIF as a continuum of responses mediated by molecular pathways that may be amenable to interventions. Preliminary evidence suggests ...

New York, USA, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight ...

Now, however, the challenge is to prove that fibrosis can be reversed by a direct attack on the pathways of fibrogenesis and matrix degradation, instead of therapy directed only to the primary ...

The transcription factor sex-determining region Y-related high-mobility group-box gene 9 (SOX9) plays a critical role in ...